Gastrointestinal and pancreatic neuroendocrine tumors, also known as gastroenteropancreatic
neuroendocrine tumors, are a rare type of cancer.
Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic
neuroendocrine tumours and its relationship to let-7 downregulation.
Somatostatin-receptor scintigraphy in gastroenteropancreatic
in 2015, a potential treatment for gastroenteropancreatic
neuroendocrine tumors (GEP NETs).
Expression of somatostatin receptors and sympathoadrenal tumours High expression of Low expression Non-neoplastic receptors and of receptors pathology sympathoadrenal system tumours Phaeochromocytoma Breast Autoimmune carcinoma diseases Neuroblastoma Melanoma Granulomas Ganglioneuroma Lymphoma Thyroid-associated ophthalmopathy Paraganglioma Prostate Post-radiation cancer inflammatory disease Gastroenteropancreatic
Non-small-cell Bacterial tumours (GEP) cancer infections (e.
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic
Recent studies have proposed the use of new TNM staging systems (European Neuroendocrine Tumor Society staging system) and biomarkers (Ki-67, cytokeratin 19, Cox-2, and epidermal growth factor receptor) to stratify gastroenteropancreatic
NETs into categories with prognostic relevance.
Guidelines for the management of gastroenteropancreatic
neuroendocrine (including carcinoid) tumors.
Neuroendocrine tumors of the gastroenteropancreatic
system (NET-GEP) correlation between Ki-67 immunostaining, histological features and clinical behaviour.
Novartis, Basel, Switzerland, has announced that the Japanese health authority has approved Sandostatin LAR (octreotide acetate for injectable suspension) for the treatment of acromegaly and pituitary gigantism which is unresponsive to or unsuitable for surgery or other drug therapies, and for symptoms associated with gastrointestinal hormone secreting tumors (also known as gastroenteropancreatic
(GEP) neuroendocrine tumors (NET), including carcinoid tumors, gastrinomas, and VIPomas (Vasoactive Intestinal Peptide- secreting tumors).
Combination therapy with octreotide and [alpha]-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic
Efficacy and Safety of Lanreotide Depot vs Placebo in Patients With Neuroendocrine Tumor and a History of Carcinoid Syndrome and Prior Octreotide Therapy This presentation is a subanalysis of the ELECT study which tested treatment with lanreotide depot for symptomatic control of carcinoid syndrome in patients with gastroenteropancreatic
neuroendocrine tumors against a placebo treatment.